Join the club for FREE to access the whole archive and other member benefits.

Vivodyne pioneers drug development with lab-grown organs with $38M funding

Offers over 20 innovative organ models for realistic testing and collaborating

22-Nov-2023

Key points from article :

Vivodyne, founded by University of Pennsylvania bioengineers, secures $38 million seed financing led by Khosla Ventures.

The platform uses lab-grown human organs to test drugs before they enter clinical trials.

Vivodyne's technology can generate realistic, scalable, and reproducible human data in weeks.

The company has developed over 20 human organ models that mimic native human functions.

Vivodyne's platform can cultivate, dose, and image over 8,000 individual tissues simultaneously.

The company's technology has already attracted collaborations with a majority of the top 10 large pharmaceutical companies.

Mentioned in this article:

Click on resource name for more details.

Khosla Ventures

Venture Capital & Private Equity company

Vivodyne

Ultra-scalable drug testing on lab-grown human tissues

Topics mentioned on this page:
Investments, Laboratory Automation
Vivodyne pioneers drug development with lab-grown organs with $38M funding